BGMD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BGMD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
BG Medicine's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2015 was $0.00 Mil. BG Medicine's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2015 was $0.00 Mil. BG Medicine's annualized EBITDA for the quarter that ended in Dec. 2015 was $-3.54 Mil. BG Medicine's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2015 was 0.00.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for BG Medicine's Debt-to-EBITDA or its related term are showing as below:
The historical data trend for BG Medicine's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BG Medicine Annual Data | |||||||||||||||||||||
Trend | Dec05 | Dec06 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | |||||||||||
Debt-to-EBITDA | Get a 7-Day Free Trial | - | -0.44 | -0.50 | -0.41 | - |
BG Medicine Quarterly Data | ||||||||||||||||||||
Mar11 | Jun11 | Sep11 | Dec11 | Mar12 | Jun12 | Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | |
Debt-to-EBITDA | Get a 7-Day Free Trial | -0.64 | -0.38 | -0.22 | - | - |
For the Medical Instruments & Supplies subindustry, BG Medicine's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, BG Medicine's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BG Medicine's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
BG Medicine's Debt-to-EBITDA for the fiscal year that ended in Dec. 2015 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (0 | + | 0) | / | -5.057 | |
= | 0.00 |
BG Medicine's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2015 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (0 | + | 0) | / | -3.536 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2015) EBITDA data.
BG Medicine (OTCPK:BGMD) Debt-to-EBITDA Explanation
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
Be Aware
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of BG Medicine's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeffrey R Luber | director | 100 CAMPUS DRIVE, C/O EXACT SCIENCES CORP, MARLBOROUGH MA 01752 |
Noubar Afeyan | director, 10 percent owner | C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142 |
Stelios Papadopoulos | director | 3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020 |
Harry W Wilcox | director | ONE KENDALL SQ, BLDG 700, CAMBRIDGE MA 02139 |
Agtc Partners, L.p. | 10 percent owner | C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142 |
Newcogen Group, Inc. | 10 percent owner | C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142 |
Applied Genomic Technology Capital Fund Lp | 10 percent owner | C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142 |
Flagship Pioneering Inc. | 10 percent owner | 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142 |
Agtc Advisors Fund Lp | 10 percent owner | ONE MEMORIAL DRIVE 7TH FLOOR CAMBRIDGE MA 02142 |
Kania Edwin M Jr | 10 percent owner | |
Flagship Ventures Fund 2007, L.p. | 10 percent owner | 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142 |
Flagship Ventures 2007 General Partner Llc | 10 percent owner | 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142 |
Brian S Posner | director | 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142 |
Stephane Bancel | director | 320 BENT STREET, CAMBRIDGE MA 02141 |
Harris Timothy J.r. | director | C/O BG MEDICINE, 610 LINCOLN STREET NORTH, WALTHAM MA 02451 |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.